Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract 3364: Preclinical evaluation of BiTE^®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer

Julie M. Bailis, Petra Lutterbuese, Oliver Thomas, Kathrin Locher, John Harrold, Michael Boyle, Joachim Wahl, Shyun Li, Alexander Sternjak, Anja Henn, Christoph Dahlhoff, Virginie Naegele, Benno Rattel, Tobias Raum, Angela Coxon

Cancer Res (2020) 80 (16_Supplement): 3364.

https://doi.org/10.1158/1538-7445.AM2020-3364

Published: 15 August 2020

View articletitled, Abstract 3364: Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer

Journal Articles

Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing

Cancer Res (2017) 77 (13_Supplement): 55.

https://doi.org/10.1158/1538-7445.AM2017-55

Published: 01 July 2017

View articletitled, Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing

Journal Articles

Abstract 3630: Preclinical evaluation of a BiTE® antibody construct with extended half-life that targets the tumor differentiation marker mesothelin

Alexander Sternjak, Fei Lee, Joachim Wahl, Dan Rock, Oliver Thomas, Sabine Stienen, Ralf Lutterbuese, Patrick Hoffmann, Tobias Raum, Peter Kufer, Benno Rattel, Angela Coxon, Matthias Friedrich, Julie Bailis

Cancer Res (2017) 77 (13_Supplement): 3630.

https://doi.org/10.1158/1538-7445.AM2017-3630

Published: 01 July 2017

View articletitled, Abstract 3630: Preclinical evaluation of a BiTE® antibody construct with extended half-life that targets the tumor differentiation marker mesothelin

Journal Articles

Abstract 3526: Subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice

Matthias Friedrich, Petra Deegen, Markus Voelkel, Joachim Wahl, Joachim Schuhmacher, Wolfram Steinke, Dieter Zopf, Robert B. Harris, Patrick A. Baeuerle, Peter Kufer, Benno Rattel

Cancer Res (2012) 72 (8_Supplement): 3526.

https://doi.org/10.1158/1538-7445.AM2012-3526

Published: 15 April 2012

View articletitled, Abstract 3526: Subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice

Journal Articles

Abstract 3523: Preclinical characterization of MT114, a novel CD33/CD3-bispecific BiTE antibody for the treatment of acute myeloid leukemia (AML)

Anja Henn, Matthias Friedrich, Roman Kischel, Ralf Lutterbuese, Katja Schneider, Peter Mueller, Patrick A. Baeuerle, Tobias Raum, Peter Kufer, Benno Rattel

Cancer Res (2012) 72 (8_Supplement): 3523.

https://doi.org/10.1158/1538-7445.AM2012-3523

Published: 15 April 2012

View articletitled, Abstract 3523: Preclinical characterization of MT114, a novel CD33/CD3-bispecific BiTE antibody for the treatment of acute myeloid leukemia (AML)

Journal Articles

Abstract 4561: Preclinical characterization of MT112/BAY 2010112, a novel PSMA/CD3-bispecific BiTE antibody for the treatment of prostate cancer

Ralf Lutterbuese, Matthias Friedrich, Roman Kischel, Doris Rau, Patrick Hoffmann, Evelyn Ebert, Dieter Zopf, Ricarda Finnern, Peter Mueller, Patrick A. Baeuerle, Andreas Wolf, Benno Rattel, Tobias Raum, Peter Kufer

Cancer Res (2011) 71 (8_Supplement): 4561.

https://doi.org/10.1158/1538-7445.AM2011-4561

Published: 15 April 2011

View articletitled, Abstract 4561: Preclinical characterization of MT112/BAY 2010112, a novel PSMA/CD3-bispecific BiTE antibody for the treatment of prostate cancer

Journal Articles

Abstract 5625: In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas

Stacy R. Fuhrmann, Maria Amann, Kathy Mulgrew, Grit Lorenczewski, Raffaele Baffa, Andreas Wolf, Michael Oberst, Benno Rattel, Petra Lutterbuese, Patrick Baeuerle, Bahija Jallal, Pamela Trail, Laura Richman, Steven Coats, Scott A. Hammond

Cancer Res (2010) 70 (8_Supplement): 5625.

https://doi.org/10.1158/1538-7445.AM10-5625

Published: 15 April 2010

View articletitled, Abstract 5625: In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas

Journal Articles

Abstract 2435: Validation of Cynomolgus monkeys as relevant species for safety assessment of a novel human BiTE antibody platform for cancer therapy

Benno Rattel, Roman Kischel, Oliver Thomas, Matthias Friedrich, Doris Rau, Evelyn Ebert, Tobias Raum, Andreas Wolf, Susanne Mangold, Majk Kvesic, Patrick A. Baeuerle, Peter Kufer

Cancer Res (2010) 70 (8_Supplement): 2435.

https://doi.org/10.1158/1538-7445.AM10-2435

Published: 15 April 2010

View articletitled, Abstract 2435: Validation of Cynomolgus monkeys as relevant species for safety assessment of a novel human BiTE antibody platform for cancer therapy

Journal Articles

Abstract 2429: Evidence of a therapeutic window with a T cell-engaging BiTE antibody based on monoclonal antibody cetuximab

Ralf Lutterbuese, Oliver Thomas, Tobias Raum, Roman Kischel, Patrick Hoffmann, Matthias Friedrich, Grit Lorenczweski, Andreas Wolf, Thomas Urbig, Evelyn Schaller, Doris Rau, Susanne Mangold, Patrick A. Baeuerle, Peter Kufer, Benno Rattel

Cancer Res (2010) 70 (8_Supplement): 2429.

https://doi.org/10.1158/1538-7445.AM10-2429

Published: 15 April 2010

View articletitled, Abstract 2429: Evidence of a therapeutic window with a T cell-engaging BiTE antibody based on monoclonal antibody cetuximab

Journal Articles

Abstract 2433: Eradication of established pancreatic tumors in mice by engagement of extra-tumoral human T cells with BiTE antibody MT110

Matthias Friedrich, Daniela Drache, Maria Amann, Susanne Filusch, Markus Voelkel, Oliver Thomas, Patrick A. Baeuerle, Benno Rattel

Cancer Res (2010) 70 (8_Supplement): 2433.

https://doi.org/10.1158/1538-7445.AM10-2433

Published: 15 April 2010

View articletitled, Abstract 2433: Eradication of established pancreatic tumors in mice by engagement of extra-tumoral human T cells with BiTE antibody MT110

Journal Articles

Evaluation of the efficacy of satraplatin (JM216) and its major metabolite JM118 in drug resistant cells and in combination with docetaxel

Katja Wosikowski, Maureen G. Caligiuri, Faith Kaplan, Jimmy Xu, Nikolai Kley, Benno Rattel

Cancer Res (2005) 65 (9_Supplement): 324.

Published: 01 May 2005

View articletitled, Evaluation of the efficacy of satraplatin (JM216) and its major metabolite JM118 in drug resistant cells and in combination with docetaxel

Journal Articles

Cytotoxic activity of satraplatin (JM216) and its metabolites in human prostate carcinoma cell lines

Katja Wosikowski, Benno Rattel, Maureen Caligiuri, Gerhard Unteregger, Marcel Rozencweig

Cancer Res (2004) 64 (7_Supplement): 1065.

Published: 01 April 2004

View articletitled, Cytotoxic activity of satraplatin (JM216) and its metabolites in human prostate carcinoma cell lines

Journal Articles

Pharmacological activity of the fully human anti-HLA-DR antibody, 1D09C3

Zoltan A. Nagy, Benno Rattel

Cancer Res (2004) 64 (7_Supplement): 163.

Published: 01 April 2004

View articletitled, Pharmacological activity of the fully human anti-HLA-DR antibody, 1D09C3

Journal Articles

WK175, a Novel Antitumor Agent, Decreases the Intracellular Nicotinamide Adenine Dinucleotide Concentration and Induces the Apoptotic Cascade in Human Leukemia Cells

Katja Wosikowski, Karin Mattern, Isabel Schemainda, Max Hasmann, Benno Rattel, Roland Löser

Cancer Res (2002) 62 (4): 1057–1062.

Published: 01 February 2002

View articletitled, WK175, a Novel Antitumor Agent, Decreases the Intracellular Nicotinamide Adenine Dinucleotide Concentration and Induces the Apoptotic Cascade in Human Leukemia Cells

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 3364: Preclinical evaluation of BiTE^®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer

Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing

Abstract 3630: Preclinical evaluation of a BiTE® antibody construct with extended half-life that targets the tumor differentiation marker mesothelin

Abstract 3526: Subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice

Abstract 3523: Preclinical characterization of MT114, a novel CD33/CD3-bispecific BiTE antibody for the treatment of acute myeloid leukemia (AML)

Abstract 4561: Preclinical characterization of MT112/BAY 2010112, a novel PSMA/CD3-bispecific BiTE antibody for the treatment of prostate cancer

Abstract 5625: In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas

Abstract 2435: Validation of Cynomolgus monkeys as relevant species for safety assessment of a novel human BiTE antibody platform for cancer therapy

Abstract 2429: Evidence of a therapeutic window with a T cell-engaging BiTE antibody based on monoclonal antibody cetuximab

Abstract 2433: Eradication of established pancreatic tumors in mice by engagement of extra-tumoral human T cells with BiTE antibody MT110

Evaluation of the efficacy of satraplatin (JM216) and its major metabolite JM118 in drug resistant cells and in combination with docetaxel

Cytotoxic activity of satraplatin (JM216) and its metabolites in human prostate carcinoma cell lines

Pharmacological activity of the fully human anti-HLA-DR antibody, 1D09C3

WK175, a Novel Antitumor Agent, Decreases the Intracellular Nicotinamide Adenine Dinucleotide Concentration and Induces the Apoptotic Cascade in Human Leukemia Cells

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only